Streetbeat News

Analyst Ratings

CLX

Atlantic Equities analyst Edward Lewis has upgraded Clorox (NYSE:CLX) from Underweight to Neutral.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:52 pm

PCRX

Truist Securities analyst Les Sulewski has maintained a 'Buy' rating on Pacira BioSciences (NASDAQ:PCRX), but lowered the price target from $60 to $55.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:52 pm

SEDG

Truist Securities analyst Jordan Levy has maintained a 'Buy' rating on SolarEdge Technologies (NASDAQ:SEDG) but lowered the price target from $400 to $340.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:51 pm

ELF

Truist Securities analyst Bill Chappell maintains a 'Buy' rating on e.l.f. Beauty (NYSE:ELF) and raises the price target from $110 to $135.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:51 pm

VCEL

Truist Securities analyst Samuel Brodovsky has maintained a 'Hold' rating on Vericel (NASDAQ:VCEL) but lowered the price target from $42 to $39.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:51 pm

ETSY

Truist Securities analyst Youssef Squali has maintained a 'Buy' rating on Etsy (NASDAQ:ETSY) and raised the price target from $120 to $126.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 1:51 pm

MRNA

Deutsche Bank analyst Emmanuel Papadakis has downgraded Moderna (NASDAQ:MRNA) from Buy to Hold and lowered the price target from $200 to $125.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:51 pm

XYL

RBC Capital has maintained an Outperform rating on Xylem's stock but has lowered its price target from $133 to $129. This has led to a decrease in Xylem's share price.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:51 pm

BJDX

Dawson James analyst Jason Kolbert has downgraded Bluejay Diagnostics (NASDAQ:BJDX) from Buy to Neutral.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:51 pm

PYPL

PayPal Holdings Inc's (NASDAQ:PYPL) stock fell despite reporting a Q2 earnings beat. Analysts from Truist Securities, Canaccord Genuity Capital Markets, Oppenheimer, Susquehanna, and Needham weighed in on the results. While some analysts maintained a Buy rating and raised the price target, others cut the price target or maintained a Hold or Neutral rating. The analysts highlighted strong revenue, accelerating ecommerce growth, and promising new initiatives, but also noted concerns about margin pressure and the shift to lower margin unbranded revenue.

Portfolio Pulse from Priya Nigam

August 04, 2023 | 1:51 pm